复宏汉霖(02696.HK)就HLX35与BINACEA订立许可及共同开发协议
复宏汉霖(02696.HK)公布,公司与Binacea订立许可及共同开发协议。据此,公司同意基於相关知识产权,就HLX35向Binacea授出一项许可,供其於除中国大陆、香港、澳门及台湾地区以外的全球范围就所有与任何适应症相关的疾病或失调的人类的治疗、预防、治癒或管理内研究、开发、生产及商业化许可产品。
公司指,是次与Binacea合作将有利於推进公司双特异性抗体产品的研发进展,并通过共同开发和权利许可的方式扩大集团创新产品的可及性和国际影响力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.